Impact of variants of SARS-CoV-2 on obstetrical and neonatal outcomes.


Journal

Journal of gynecology obstetrics and human reproduction
ISSN: 2468-7847
Titre abrégé: J Gynecol Obstet Hum Reprod
Pays: France
ID NLM: 101701588

Informations de publication

Date de publication:
Apr 2023
Historique:
received: 08 12 2022
revised: 07 02 2023
accepted: 27 02 2023
medline: 28 3 2023
pubmed: 5 3 2023
entrez: 4 3 2023
Statut: ppublish

Résumé

SARS-CoV-2 can lead to several types of complications during pregnancy. Variant surges are associated with different severities of disease. Few studies have compared the clinical consequences of specific variants on obstetrical and neonatal outcomes. Our goal was to evaluate and compare disease severity in pregnant women and obstetrical or neonatal complications between variants of SARS-CoV-2 that have circulated in France over a two-year period (2020-2022). This retrospective cohort study included all pregnant women with a confirmed SARS-CoV-2 infection (positive naso-pharyngeal RT-PCR test) from March 12, 2020 to January 31, 2022, in three tertiary maternal referral obstetric units in the Paris metropolitan area, France. We collected clinical and laboratory data for mothers and newborns from patients' medical records. Variant identification was either available following sequencing or extrapolated from epidemiological data. There were 234/501 (47%) Wild Type (WT), 127/501 (25%) Alpha, 98/501 (20%) Delta, and 42/501 (8%) Omicron. No significative difference was found regarding two composite adverse outcomes. There were significantly more hospitalizations for severe pneumopathy in Delta variant than WT, Alpha and Omicron respectively (63% vs 26%, 35% and 6%, p<0.001), more frequent oxygen administration (23% vs 12%, 10% and 5%, p = 0,001) and more symptomatic patients at the time of testing with Delta and WT (75% and 71%) versus Alpha and Omicron variants (55% and 66% respectively, p<0.01). Stillbirth tended to be associated with variants (p = 0.06): WT 1/231 (<1%) vs 4/126 (3%), 3/94 (3%), and 1/35 (3%) in Alpha, Delta and Omicron cases respectively. No other difference was found. Although the Delta variant was associated with more severe disease in pregnant women, we found no difference regarding neonatal and obstetrical outcomes. Neonatal and obstetrical specific severity may be due to mechanisms other than maternal ventilatory and general infection.

Sections du résumé

BACKGROUND BACKGROUND
SARS-CoV-2 can lead to several types of complications during pregnancy. Variant surges are associated with different severities of disease. Few studies have compared the clinical consequences of specific variants on obstetrical and neonatal outcomes. Our goal was to evaluate and compare disease severity in pregnant women and obstetrical or neonatal complications between variants of SARS-CoV-2 that have circulated in France over a two-year period (2020-2022).
METHOD METHODS
This retrospective cohort study included all pregnant women with a confirmed SARS-CoV-2 infection (positive naso-pharyngeal RT-PCR test) from March 12, 2020 to January 31, 2022, in three tertiary maternal referral obstetric units in the Paris metropolitan area, France. We collected clinical and laboratory data for mothers and newborns from patients' medical records. Variant identification was either available following sequencing or extrapolated from epidemiological data.
RESULTS RESULTS
There were 234/501 (47%) Wild Type (WT), 127/501 (25%) Alpha, 98/501 (20%) Delta, and 42/501 (8%) Omicron. No significative difference was found regarding two composite adverse outcomes. There were significantly more hospitalizations for severe pneumopathy in Delta variant than WT, Alpha and Omicron respectively (63% vs 26%, 35% and 6%, p<0.001), more frequent oxygen administration (23% vs 12%, 10% and 5%, p = 0,001) and more symptomatic patients at the time of testing with Delta and WT (75% and 71%) versus Alpha and Omicron variants (55% and 66% respectively, p<0.01). Stillbirth tended to be associated with variants (p = 0.06): WT 1/231 (<1%) vs 4/126 (3%), 3/94 (3%), and 1/35 (3%) in Alpha, Delta and Omicron cases respectively. No other difference was found.
CONCLUSION CONCLUSIONS
Although the Delta variant was associated with more severe disease in pregnant women, we found no difference regarding neonatal and obstetrical outcomes. Neonatal and obstetrical specific severity may be due to mechanisms other than maternal ventilatory and general infection.

Identifiants

pubmed: 36870417
pii: S2468-7847(23)00033-8
doi: 10.1016/j.jogoh.2023.102566
pmc: PMC9979701
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

102566

Informations de copyright

Copyright © 2023 Elsevier Masson SAS. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of Competing Interest There are no conflicts of interest.

Auteurs

M Poisson (M)

AP-HP, Hôpital Louis Mourier, Department of Gynecology and Obstetrics, Colombes, France.

J Sibiude (J)

AP-HP, Hôpital Louis Mourier, Department of Gynecology and Obstetrics, Colombes, France; Université Paris Cité, IAME, INSERM, Paris, France; Groupe de Recherche sur les Infections pendant la Grossesse, Colombes, France; Fédération Hospitalo-Universitaire PREMA (FHU), Paris, France.

E Mosnino (E)

Division of Obstetrics and Gynecology, Antoine Béclère Hospital, Paris Saclay University Hospitals, APHP 157 rue de la Porte de Trivaux, 92140, Clamart, France.

M Koual (M)

Fédération Hospitalo-Universitaire PREMA (FHU), Paris, France; AP-HP, Hôpital Bichat, Department of Gynecology and Obstetrics, Paris, France.

L Landraud (L)

Université Paris Cité, IAME, INSERM, Paris, France; Fédération Hospitalo-Universitaire PREMA (FHU), Paris, France; AP-HP, Hôpital Louis Mourier, Department of Hygiene and Microbiology, Colombes, France.

N Fidouh (N)

AP-HP, Hôpital Bichat, Department of Virology, Paris, France.

L Mandelbrot (L)

AP-HP, Hôpital Louis Mourier, Department of Gynecology and Obstetrics, Colombes, France; Université Paris Cité, IAME, INSERM, Paris, France; Groupe de Recherche sur les Infections pendant la Grossesse, Colombes, France; Fédération Hospitalo-Universitaire PREMA (FHU), Paris, France.

C Vauloup-Fellous (C)

Saclay University, Gif-sur-Yvette, France; AP-HP, Division of Virology, Paul Brousse Hospital, Paris Saclay University Hospitals, INSERM U1193, Villejuif, France.

D Luton (D)

AP-HP, Division of Virology, Paul Brousse Hospital, Paris Saclay University Hospitals, INSERM U1193, Villejuif, France; APHP, Hôpital Bicêtre, Department of Gynecology and Obstetrics, Le Kremlin-Bicêtre, France.

A Benachi (A)

Division of Obstetrics and Gynecology, Antoine Béclère Hospital, Paris Saclay University Hospitals, APHP 157 rue de la Porte de Trivaux, 92140, Clamart, France; AP-HP, Division of Virology, Paul Brousse Hospital, Paris Saclay University Hospitals, INSERM U1193, Villejuif, France.

A J Vivanti (AJ)

Fédération Hospitalo-Universitaire PREMA (FHU), Paris, France; AP-HP, Division of Virology, Paul Brousse Hospital, Paris Saclay University Hospitals, INSERM U1193, Villejuif, France.

O Picone (O)

AP-HP, Hôpital Louis Mourier, Department of Gynecology and Obstetrics, Colombes, France; Université Paris Cité, IAME, INSERM, Paris, France; Groupe de Recherche sur les Infections pendant la Grossesse, Colombes, France; Fédération Hospitalo-Universitaire PREMA (FHU), Paris, France. Electronic address: olivier.picone@aphp.fr.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH